Finan Amanda, Dong Feng, Penn Marc Steven
Department of Molecular Biology, Case Western Reserve University, Cleveland, OH 44106, USA.
Front Biosci (Elite Ed). 2013 Jan 1;5(1):232-48. doi: 10.2741/e611.
Over the past decade the cardiovascular regenerative medicine field has made significant advances in our understanding and treatment of injured myocardium. Prior to stem cell therapy, available treatments for cardiovascular disease were unable to repair or regenerate the damaged heart. Stem cell therapy is increasingly becoming a viable option to prevent and treat cardiac dysfunction. A number of exogenous stem cell populations have been examined for their ability to participate in cardiac repair. Their application in the clinical setting will be reviewed here. The molecular pathways that work in concert to orchestrate a systemic endogenous stem cell response to cardiac injury have also begun to be defined. A potential strategy for future therapeutics is the manipulation of these endogenous pathways via pharmacological or biopharmaceutical approaches. In this review we begin to formulate the discussion that the best future therapeutic option to regenerate end organ function will be a combination of programmed stem cells and biopharmaceuticals that modulate regenerative signaling to bolster the natural in vivo cellular and signaling mechanisms.
在过去十年中，心血管再生医学领域在我们对受损心肌的理解和治疗方面取得了重大进展。在干细胞疗法出现之前，心血管疾病的现有治疗方法无法修复或再生受损心脏。干细胞疗法正日益成为预防和治疗心脏功能障碍的可行选择。许多外源性干细胞群体已被研究其参与心脏修复的能力。本文将对它们在临床环境中的应用进行综述。协同作用以协调全身内源性干细胞对心脏损伤反应的分子途径也已开始被明确。未来治疗的一个潜在策略是通过药理学或生物制药方法操纵这些内源性途径。在本综述中，我们开始阐述这样的观点，即未来再生终末器官功能的最佳治疗选择将是程序化干细胞和生物制药的组合，这些生物制药可调节再生信号以增强体内天然的细胞和信号机制。
